Renal tolerability of iopromide and iodixanol in 562 renally impaired patients undergoing cardiac catheterisation: the DIRECT study

Chen, Yundai; Hu, Shunying; Yin, Long; Zhao, Ru; Wang, Lefeng; Fu, Guosheng; He, Qing; Su, Xi; Zheng, Yang; Qi, Xiangqian; Liu, Huiliang; Wang, Jianan; Gao, Wei; Wang, Mingsheng; Liu, Shaowen; Zheng, Xiaohui; He, Ben; Yang, Ping; Zhou, Sijie; Gao, Chuanyu; Qiu, Chunguang

doi:10.4244/eijv8i7a126

Cited by 19 publications

(15 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pugh et al (1993) compared iopromide and iodixanol for femoral arteriography; according to McCullough et al (2006a, b) they found a lower rate of CIN after iopromide than after iodixanol. Chen et al (2012) did not find any difference in nephrotoxicity between iopromide and iodixanol in patients undergoing coronary angiography who had moderately reduced renal dysfunction. These conflicting results are typical of this topic.…”

Section: Non-ionic Contrast Mediamentioning

confidence: 87%

Contrast Medium-Induced Nephropathy

Thomsen¹,

Stacul²,

Webb³

2014

Medical Radiology

View full text Add to dashboard Cite

Section: Non-ionic Contrast Mediamentioning

confidence: 87%

Contrast Medium-Induced Nephropathy

Thomsen¹,

Stacul²,

Webb³

2014

Medical Radiology

View full text Add to dashboard Cite

“…In this study, we named, i.e. Chen (1) 2012 that meant Chen 2012 [ 19 ] with the data of relative CIN criterion, while the Chen (2) 2012 meant the absolute criterion.…”

Section: Methodsmentioning

confidence: 99%

Contrast-induced nephropathy in patients with diabetes mellitus between iso- and low-osmolar contrast media: A meta-analysis of full-text prospective, randomized controlled trials

et al. 2018

View full text Add to dashboard Cite

PurposeThis study was conducted to compare iso-osmolar contrast medium, iodixanol, with low-osmolar contrast media (LOCM) for assessing contrast-induced nephropathy (CIN) incidence, exclusively in the diabetic population.MethodA systematic search was conducted for full-text, prospective, randomized controlled trials (RCTs). The primary outcome was incidence of CIN. Medline, Cochrane Central Register of Controlled Trials, and other sources were searched until May 31, 2017.ResultsTwelve RCTs finally met the search criteria. Iodixanol did not significantly reduce the risk of CIN (risk ratio [RR]: 0.72, 95% confidence interval (CI): [0.49, 1.04], p = 0.08). However, there was significantly reduced risk of CIN when iodixanol was compared to a LOCM agent iohexol (RR: 0.32, 95% CI [0.12, 0.89]). There were no differences between iodixanol and the other non-iohexol LOCM (RR: 0.92, 95% CI [0.68, 1.25]).ConclusionIn diabetic populations, iodixanol is not associated with a significant reduction of CIN risk. Iodixanol is associated with a reduced risk of CIN compared with iohexol, whereas no significant difference between iodixanol and other LOCM could be found.

show abstract

“…Therefore, the change of absolute or relative SCr concentration remains a key parameter in the diagnosis of CIN. Intravenous saline hydration and the use of low-osmolality contrast medium has been accepted as preventive strategies for CIN (49–51). …”

Section: Discussionmentioning

confidence: 99%

Oral N-acetylcysteine for prophylaxis of contrast-induced nephropathy in patients following coronary angioplasty: A meta-analysis

Jin

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

It is acknowledged that contrast-induced nephropathy (CIN) is a common cause of acute renal insufficiency after cardiac catheterization and affects mortality and morbidity. To date, it is unknown whether oral N-acetylcysteine (NAC) is able to prevent contrast-induced nephropathy (CIN) in patients undergoing coronary angioplasty. A meta-analysis of randomized controlled trials was performed to assess the effects of NAC in the prevention of CIN in patients following coronary angioplasty. A total of 19 studies published prior to January 2015 that investigated the efficacy of oral NAC for the prevention of CIN were collected from Medline, Cochrane and Embase databases and conference proceedings from cardiology and nephrology meetings. The primary point of investigation was CIN, and the secondary points were renal failure requiring dialysis, mortality and length of hospitalization. The meta-analysis was performed using fixed- or random-effect models according to heterogeneity. Up to January 2015, 19 randomized placebo-controlled clinical trials met the inclusion criteria for the meta-analysis, including 4,514 patients. The pooled data showed that oral NAC did not reduce the CIN incidence [relative risk 0.84, 95% confidence interval (CI) 0.65–1.10; P=0.20], without heterogeneity among trials (I2=29%). Thus, the present meta-analysis suggests that oral NAC therapy is not effective as an alternative treatment to prevent CIN in patients following angioplasty. Further high quality randomized clinical controlled trials are required to confirm the usage and availability of this treatment.

show abstract

Renal tolerability of iopromide and iodixanol in 562 renally impaired patients undergoing cardiac catheterisation: the DIRECT study

Abstract: With rigorous hydration, the CIN incidence was very low in patients with moderate renal dysfunction who underwent coronary angiography or PCI. No difference in nephrotoxicity was found between iopromide and iodixanol.

Cited by 19 publications

References 29 publications

Contrast Medium-Induced Nephropathy

Contrast Medium-Induced Nephropathy

Contrast-induced nephropathy in patients with diabetes mellitus between iso- and low-osmolar contrast media: A meta-analysis of full-text prospective, randomized controlled trials

Oral N-acetylcysteine for prophylaxis of contrast-induced nephropathy in patients following coronary angioplasty: A meta-analysis

Contact Info

Product

Resources

About